Sökresultat
AlzeCure presenterar nya data på IASP 2024
…he presentation includes new preclinical results describing the properties of the recently selected drug candidate for TrkA-NAM, ACD137. The data show that the substance is a potent and selective negative modulator of NGF/TrkA signaling in cell-based assays. New data in several different preclinical pain models also show clear and significant analgesic effects of ACD137. ”The target mechanism in the project has strong validation in pain, both prec…
Ultomiris rekommenderas för godkännande i EU av CHMP för behandling av vuxna med generell myasthenia gravis
…paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uraemic syndrome (aHUS). The most common adverse drug reactions are diarrhoea, upper respiratory tract infection, nasopharyngitis and headache.1 The CHMP recommended approval as an add-on to standard therapy for the treatment of adult patients with gMG who are AChR antibody-positive. Ultomiris was approved in the US for adults with gMG who are AChR antibody-positive in April 2022,…
ANS In Real Life
…är en uteslutningsdiagnos när allvarligare tillstånd har uteslutits som CNS-infektioner, autoimmun encefalit eller reversibelt vasokonstriktionssyndrom. ETIK Etiska överväganden var ett återkommande tema när mötets deltagare diskuterade under frågestunder i samband med de två dagarnas föreläsningar. Tydligast blev detta när intensivvårdsläkaren Helena Almén från Akademiska sjukhuset gav sin syn på den akuta handläggningen av intracerebrala hematom…
MS Expert Discussion Forum
…Neurology Laura Airas University of Turku Professor of Neuroimmunology Morten Blinkenberg Danish Multiple Sclerosis Center, Copenhagen University Hospital Senior consultant Veronica Popescu University MS Centre Pelt-Hasselt Professor of Clinical Neuroimmunology…
Vetenskaplig artikel om positiva kliniska resultat med Painless ACD440 mot neuropatisk smärta
…ic effect, and over a long period of time. ”The publication shows the proof-of mechanism for ACD440, i.e. that the substance has a high and significant pain-relieving effect. Combined with our Phase IIa clinical data in chronic patients with peripheral neuropathic pain, this strengthens the continued development opportunities for ACD440,” said Märta Segerdahl, CMO at AlzeCure Pharma. “There is a great medical need for effective and safe non-opioid…